CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [81]
In the citing paper
“but correlations between in vivo CSF tau biomarkers and tau aggregates in postmortem tissue are weaker (11).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [11]
In the citing paper
“levels of CSF tau and phosphorylated tau (ptau) species are elevated in DAT8, 13, 14 and are hypothesized to reflect the presence of neurofibrillary tangles and/or neurodegeneration,15, 16 although not all studies support this conclusion.17”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [16]
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“A staging system of Alzheimer’s-associated neurofibrillary pathology using immunohistochemistry and AT8 has been suggested (Braak et al., 2006).”
BackgroundMethodSelf-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“Whereas NFTs and neuritic processes are composed of fibrils containing phosphorylated tau, plaques consist mostly of fibrillous beta-amyloid (Grundke-Iqbal et al., 1986; Lee et al., 1991; Dickson, 1997).”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and Harald Hampel1 1Deme…”
BackgroundMethodResultInfluentialSelf-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
Items 201–300 of 584
Ewers, M., Schmitz, S., Hansson, O., Walsh, C., Fitzpatrick, A., Bennett, D., Minthon, L., Trojanowski, J. Q., Shaw, L. M., Faluyi, Y. O., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.005 · Cited by 65
Self-citationHarnessing neuroplasticity: modern approaches and clinical future
Sasmita, A. O., Kuruvilla, J., & Ling, A. P. K. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1466781 · Cited by 74
Leoni, V., Solomon, A., & Kivipelto, M. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381021 · Cited by 65
Lithium as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective
Hampel, H., Lista, S., Mango, D., Nisticò, R., Perry, G., Avila, J., Hernandez, F., Geerts, H., Vergallo, A., (APMI), A. P. M. I., et al. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190197 · Cited by 65
Self-citationClinical and research diagnostic criteria for Alzheimer's disease
Sarazin, M., de Souza, L. C., Lehéricy, S., & Dubois, B. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.004 · Cited by 64
Nu, T. T. V., Tran, N. H. T., Nam, E., Nguyen, T. T., Yoon, W. J., Cho, S., Kim, J., Chang, K.-A., & Ju, H. (2018) · RSC Advances · doi:10.1039/c7ra11637c · Cited by 67
Challenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 88
Initiative, F. T. A. D. N., Han, S. D., Gruhl, J., Beckett, L., Dodge, H. H., Stricker, N. H., Farias, S., & Mungas, D. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9177-0 · Cited by 62
Hoeijmakers, L., Lesuis, S. L., Krugers, H. J., Lucassen, P. J., & Kőrösi, A. (2018) · Neurobiology of Stress · doi:10.1016/j.ynstr.2018.02.003 · Cited by 71
Applying fluid biomarkers to Alzheimer's disease
Zetterberg, H. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00007.2017 · Cited by 61
Chin, K. S., Yassi, N., Churilov, L. P., Masters, C. L., & Watson, R. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.030 · Cited by 67
Hu, H., Initiative, A. D. N., Chen, K.-L., Ou, Y.-N., Cao, X.-P., Chen, S.-D., Cui, M., Dong, Q., Tan, L., & Yu, J.-T. (2019) · Aging · doi:10.18632/aging.102220 · Cited by 59
Sauvée, M., DidierLaurent, G., Latarche, C., Escanyé, M.-C., Olivier, J.-L., & Malaplate-Armand, C. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-131838 · Cited by 58
Hertze, J., Nägga, K., Minthon, L., & Hansson, O. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-64 · Cited by 57
Alzheimer's disease in a dish: promises and challenges of human stem cell models
Young, J. E., & Goldstein, L. S. B. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds319 · Cited by 57
Saint-Aubert, L., Almkvist, O., Chiotis, K., Almeida, R., Wall, A., & Nordberg, A. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0204-z · Cited by 57
Salivary gland dysfunction and salivary redox imbalance in patients with Alzheimer’s disease
Zalewska, A., Klimiuk, A., Zięba, S., Wnorowska, O., Rusak, M., Waszkiewicz, N., Szarmach, I. J., Dzierżanowski, K., & Maciejczyk, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-03456-9 · Cited by 68
Menopause hormone therapy significantly alters pathophysiological biomarkers of Alzheimer's disease
Depypere, H. T., Vergallo, A., Lemercier, P., Lista, S., Benedet, A. L., Ashton, N. J., Cavedo, E., Zetterberg, H., Blennow, K., Vanmechelen, E., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12759 · Cited by 69
Self-citationPaterson, R. W., Toombs, J., Slattery, C. F., Nicholas, J. M., Andréasson, U., Magdalinou, N. K., Blennow, K., Warren, J. D., Mummery, C. J., Rossor, M. N., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7904-3 · Cited by 61
Öhrfelt, A., Johansson, P., Wallin, A., Andréasson, U., Zetterberg, H., Blennow, K., & Svensson, J. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000447239 · Cited by 63
Sleep spindle abnormalities related to Alzheimer's disease: a systematic mini-review
Weng, Y.-Y., Lei, X., & Yu, J. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.07.044 · Cited by 66
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
Lantero‐Rodriguez, J., Snellman, A., Benedet, A. L., Milà‐Alomà, M., Camporesi, E., Montoliu‐Gaya, L., Ashton, N. J., Vrillon, A., Karikari, T. K., Gispert, J. D., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202115098 · Cited by 56
Buerger, K., Alafuzoff, I., Ewers, M., Pirttila, T., Zinkowski, R., & Hampel, H. (2007) · Brain · doi:10.1093/brain/awm140 · Cited by 56
Self-citationHaense, C., Buerger, K., Kalbe, E., Drzezga, A., Teipel, S. J., Markiewicz, P., Herholz, K., Heiss, W. D., & Hampel, H. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02274.x · Cited by 55
Self-citationEl‐Obeid, A., Laurell, K., Cesarini, K. G., & Alafuzoff, I. I. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000191 · Cited by 59
Self-citationAmyloid Pathology Influences Aβ1-42 Cerebrospinal Fluid Levels in Dementia with Lewy Bodies
Slaets, S., Le Bastard, N., Theuns, J., Sleegers, K., Verstraeten, A., De Leenheir, E., Luyckx, J., Martin, J.-J., Van Broeckhoven, C., & Engelborghs, S. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122176 · Cited by 55
Initiative, F. T. A. D. N., Stricker, N. H., Dodge, H. H., Dowling, N. M., Han, S. D., Erosheva, E. A., & Jagust, W. J. (2012) · Brain Imaging and Behavior · doi:10.1007/s11682-012-9171-6 · Cited by 52
Salivary biomarkers in Alzheimer’s disease
Tvarijonaviciute, A., Zamora, C., Cerón, J. M. C., Bravo-Cantero, A. F., Pardo-Marín, L., Mateo, S. V., & López‐Jornet, P. (2020) · Clinical Oral Investigations · doi:10.1007/s00784-020-03214-7 · Cited by 64
Liu, C., Chyr, J., Zhao, W., Xu, Y., Ji, Z., Tan, H., Soto, C. A., Zhou, X., & Initiative, A. D. N. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00410 · Cited by 55
Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease
Trelle, A. N., Carr, V. A., Wilson, E. N., Swarovski, M. S., Hunt, M. P., Toueg, T. N., Tran, T., Channappa, D., Corso, N. K., Thieu, M. K., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011477 · Cited by 54
Rethinking on the concept of biomarkers in preclinical Alzheimer’s disease
Berti, V., Polito, C., Lombardi, G., Ferrari, C., Sorbi, S., & Pupi, A. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2477-1 · Cited by 55
Xu, M., Sanz, D. L., Garcés, P., Maestú, F., Li, Q., & Pantazis, D. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3049199 · Cited by 63
Krell‐Roesch, J., Rakuša, M., Syrjanen, J. A., van Harten, A. C., Lowe, V. J., Jack, C. R., Kremers, W. K., Knopman, D. S., Stokin, G. B., Petersen, R. C., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12557 · Cited by 57
Cerebrospinal fluid β-amyloid42 and neurofilament light relate to white matter hyperintensities
Osborn, K. E., Liu, D., Samuels, L. R., Moore, E. E., Cambronero, F. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gordon, E. A., Pechman, K. R., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.028 · Cited by 51
Obrocki, P., Khatun, A., Ness, D., Senkevich, K. A., Hanrieder, J., Capraro, F., Mattsson, N., Andréasson, U., Portelius, E., Ashton, N. J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00586-6 · Cited by 56
The development of effective biomarkers for Alzheimer's disease: a review
Henry, M. S., Passmore, A. P., Todd, S., McGuinness, B., Craig, D., & Johnston, J. A. (2013) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3829 · Cited by 49
Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults
Mattsson, N., Insel, P., Nosheny, R., Trojanowski, J. Q., Shaw, L. M., Jack, C. R., Tosun, D., & Weiner, M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.027 · Cited by 49
Turk, K. W., Geada, A., Alvarez, V. E., Xia, W., Cherry, J. D., Nicks, R., Meng, G., Daley, S. A., Tripodis, Y., Huber, B. R., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00976-y · Cited by 54
Biological markers for early detection and pharmacological treatment of Alzheimer's disease
Hampel, H., Broich, K., Hoessler, Y., & Pantel, J. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/hhampel · Cited by 49
Self-citationExpression of Tau40 Induces Activation of Cultured Rat Microglial Cells
Wang, L., Jiang, Q., Chu, J., Lin, L., Li, X.-G., Chai, G.-S., Wang, Q., Wang, J.-Z., & Tian, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076057 · Cited by 47
“Total tau and hyperphosphorylated tau in cerebrospinal fluid (CSF) have been shown to correlate with neurofibrillary pathology in AD [90,91].”
BackgroundMüller, E. G., Edwin, T. H., Stokke, C., Navelsaker, S. S., Babovic, A., Bogdanovic, N., Knapskog, A. B., & Revheim, M. E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0221365 · Cited by 47
Jang, H., Park, J., Woo, S., Kim, S., Kim, H. J., Na, D. L., Lockhart, S. N., Kim, Y., Kim, K. W., Cho, S. H., et al. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101941 · Cited by 46
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Babić, M., Švob Štrac, D., Mück-Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 45
AMPK: Potential Therapeutic Target for Alzheimer's Disease
Yang, L., Jiang, Y., Shi, L., Zhong, D., Li, Y., Li, J., & Jin, R. (2020) · Current Protein & Peptide Science · doi:10.2174/1389203720666190819142746 · Cited by 46
Laske, C., Stransky, E., Fritsche, A., Eschweiler, G. W., & Leyhe, T. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-0838-3 · Cited by 58
Ceravolo, R., Borghetti, D., Kiferle, L., Tognoni, G., Giorgetti, A., Neglia, D., Sassi, N., Frosini, D., Rossi, C. A., Petrozzi, L., et al. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.01.010 · Cited by 46
Human disease biomarker panels through systems biology
Smith, B. J., Silva-Costa, L. C., & Martins‐de‐Souza, D. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00849-y · Cited by 46
Dumurgier, J., Paquet, C., Benisty, S., Kiffel, C., Lidy, C., Mouton‐Liger, F., Chabriat, H., Laplanche, J., & Hugon, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.007 · Cited by 51
Spiegel, J., Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Saint Louis, L. A., Randall, C., Butler, T., Xu, J., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150167 · Cited by 45
“[5, 6] reported that CSF P-tau231 was more strongly associated with neocortical neurofibrillary pathology than P-tau181.”
Self-citationTarga, A., Dakterzada, F., Benitez, I. D., Ortega, R. L., Pujol, M., Dalmases, M., Arias, A., Sánchez‐de‐la‐Torre, M., Zetterberg, H., Blennow, K., et al. (2020) · SLEEP · doi:10.1093/sleep/zsaa147 · Cited by 53
Mah, D., Zhao, J., Liu, X., Zhang, F., Liu, J., Wang, L., Linhardt, R. J., & Wang, C. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.671458 · Cited by 58
Alzheimer CSF biomarkers in routine clinical setting: Alzheimer’s disease CSF biomarkers
Tabaraud, F., Leman, J. P., Milor, A. M., Roussie, J. M., Barrière, G., Tartary, M., Boutros-Toni, F., & Rigaud, M. (2012) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01592.x · Cited by 44
Nakajima, M., Miyajima, M., Ogino, I., Akiba, C., Kawamura, K., Kamohara, C., Fusegi, K., Harada, Y., Hara, T., Sugano, H., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180557 · Cited by 47
Gibbons, G. S., Kim, S., Robinson, J. L., Changolkar, L. N., Irwin, D. J., Shaw, L. M. J., Lee, V. M. ‐., & Trojanowski, J. Q. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0687-5 · Cited by 47
Why bother using non-human primate models of cognitive disorders in translational research?
Camus, S. M. J., Ko, W. K. D., Pioli, E. Y., & Bézard, E. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.06.012 · Cited by 45
Frank, B. E., Ally, M., Brekke, B., Zetterberg, H., Blennow, K., Sugarman, M. A., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12508 · Cited by 42
Cao, L.-L., Guan, P.-P., Liang, Y.-Y., Huang, X.-S., & Wang, P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00108 · Cited by 42
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Goldhardt, O., Warnhoff, I., Yakushev, I. Y., Begcevic, I., Förstl, H., Magdolen, V., Soosaipillai, A. R., Diamandis, E. P., Alexopoulos, P., & Grimmer, T. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0168-6 · Cited by 45
Le Bastard, N., Aerts, L., Sleegers, K., Martin, J.-J., Van Broeckhoven, C., De Deyn, P. P., & Engelborghs, S. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-110029 · Cited by 42
Tau Related Pathways as a Connecting Link between Epilepsy and Alzheimer’s Disease
Paudel, Y. N., Angelopoulou, E., Jones, N. C., O'Brien, T. J., Kwan, P., Piperi, C., Othman, I., & Shaikh, M. F. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00460 · Cited by 44
The Emerging Role of Circular RNAs in Alzheimer’s Disease and Parkinson’s Disease
Zhang, M., & Bian, Z. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.691512 · Cited by 47
Associating Alzheimer’s disease pathology with its cerebrospinal fluid biomarkers
Bridel, C., Somers, C., Sieben, A., Rozemüller, A. J. M., Niemantsverdriet, E., Struyfs, H., Vermeiren, Y., Broeckhoven, C. V., Deyn, P. P. D., Bjerke, M., et al. (2022) · Brain · doi:10.1093/brain/awac013 · Cited by 42
Developing pharmacological therapies for Alzheimer disease
Iqbal, K., & Grundke, I. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7221-9 · Cited by 46
Nascimento, C., Di Lorenzo Alho, A. T., Bazan Conceição Amaral, C., Leite, R. E. P., Nitrini, R., Jacob‐Filho, W., Pasqualucci, C. A., Hokkanen, S. R. K., Hunter, S., Keage, H., et al. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12430 · Cited by 41
Holbrook, A. J., Tustison, N. J., Márquez, F., Roberts, J. M., Yassa, M. A., Gillen, D. L., & Initiative, A. D. N. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12068 · Cited by 56
Bridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 48
CSF P-Tau181 and Other Biomarkers in Patients With Neuronal Intranuclear Inclusion Disease
Kurihara, M., Komatsu, H., Sengoku, R., Shibukawa, M., Morimoto, S., Matsubara, T., Arakawa, A., Orita, M., Ishibashi, K., Mitsutake, A., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000201647 · Cited by 42
Prognostic value of amyloid PET scan in normal pressure hydrocephalus
Jang, H., Park, S. B., Kim, Y., Kim, K. W., Lee, J. I., Kim, S. T., Lee, K. H., Kang, E., Choe, Y. S., Seo, S. W., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8650-5 · Cited by 41
Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's disease
Bera, A., Lavanya, G., Reshmi, R., Dev, K., & Kumar, R. K. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15611 · Cited by 44
Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies
Boström, F., Hansson, O., Blennow, K., Gerhardsson, L., Lundh, T., Minthon, L., Zetterberg, H., & Londos, E. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000249145 · Cited by 43
Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
Omar, S. H., & Preddy, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030063 · Cited by 44
CSF biomarkers in neurodegenerative and vascular dementias
Llorens, F., Schmitz, M., Ferrer, I., & Zerr, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.003 · Cited by 49
Involvement of tau phosphorylation in traumatic brain injury patients
Yang, W.-J., Chen, W., Chen, L., Guo, Y.-J., Zeng, J.-S., Li, G.-Y., & Tong, W.-S. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12644 · Cited by 43
Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease
Pettigrew, C. A., Soldan, A., Sloane, K. L., Cai, Q., Wang, J., Wang, M., Moghekar, A., Miller, M. I., & Albert, M. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.08.022 · Cited by 45
Longitudinal Sensitivity of Alzheimer’s Disease Severity Staging
Benoit, J. S., Chan, W., Piller, L. B., & Doody, R. S. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317520918719 · Cited by 45
Schindler, S. E., & Fagan, A. M. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00142 · Cited by 45
Pottiez, G., Yang, L., Stewart, T., Song, N., Aro, P., Galasko, D. R., Quinn, J. F., Peskind, E. R., Shi, M., & Zhang, J. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00829 · Cited by 37
“On the contrary, tau and phosphorylated tau increase in CSF of AD patients, with at least some tau forms correlating with the formation of tangles (10), (8), (11).”
Alzheimer disease seen through the lens of sex and gender
Castro‐Aldrete, L., Einsiedler, M., Martínková, J., Depypere, H. T., Ang, T. F. A., Mielke, M. M., Sindi, S., Eyre, H. A., Au, R., Dimech, A. S., et al. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01071-0 · Cited by 49
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
Mukaetova-Ladinska, E. B., Monteith, R., & Perry, E. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/536538 · Cited by 44
A new generation of AD biomarkers: 2019 to 2021
Hawksworth, J. I., Fernández, E., & Gevaert, K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101654 · Cited by 37
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.11.038 · Cited by 36
Retinal Dysfunction in Alzheimer’s Disease and Implications for Biomarkers
Liao, C., Xu, J., Chen, Y., & Ip, N. Y. (2021) · Biomolecules · doi:10.3390/biom11081215 · Cited by 44
Feng, F., Huang, W., Meng, Q., Hao, W., Yao, H., Zhou, B., Guo, Y., Zhao, C., An, N., Wang, L., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.705030 · Cited by 37
Alzheimer's disease — Recent biomarker developments in relation to updated diagnostic criteria
Höglund, K., Fourier, A., Perret‐Liaudet, A., Zetterberg, H., Blennow, K., & Portelius, E. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.01.041 · Cited by 46
The emerging agenda of stratified medicine in neurology
Matthews, P. M., Edison, P., Geraghty, O. C., & Johnson, M. R. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.245 · Cited by 39
Occlusal Disharmony Increases Amyloid-β in the Rat Hippocampus
Ekuni, D., Tomofuji, T., Irie, K., AZUMA, T., Endo, Y., Kasuyama, K., & Morita, M. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8151-0 · Cited by 38
Henderson, T. A. (2012) · CNS Spectrums · doi:10.1017/s1092852912000636 · Cited by 41
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
Zetterberg, H., & Blennow, K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129035 · Cited by 36
Svenningsson, A. L., Stomrud, E., Insel, P. S., Mattsson, N., Palmqvist, S., & Hansson, O. (2019) · Scientific Reports · doi:10.1038/s41598-019-47638-y · Cited by 39
Zeng, P. H., Su, H.-F., Ye, C., Qiu, S.-W., Shi, A., Wang, J., Zhou, X., & Tian, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877806 · Cited by 35
Biological markers of Alzheimer?s disease
de Souza, L. C., Sarazin, M., Teixeira, A. L., Caramelli, P., dos Santos, A. M., & Dubois, B. (2014) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130233 · Cited by 43
Kaur, K., Kulkarni, Y. A., & Wairkar, S. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148905 · Cited by 38
Tao, R., Lu, Z., Ding, D., Fu, S., Hong, Z., Liang, X., Zheng, L., Xiao, Y., & Zhao, Q. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.04.003 · Cited by 41
Álvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021226 · Cited by 32
Timmers, M., Barão, S., Van Broeck, B., Tesseur, I., Slemmon, J., De Waepenaert, K., Bogert, J., Shaw, L. M., Engelborghs, S., Moechars, D., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160829 · Cited by 32
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Giacomucci, G., Mazzeo, S., Crucitti, C., Ingannato, A., Bagnoli, S., Padiglioni, S., Galdo, G., Emiliani, F., Frigerio, D., Moschini, V., et al. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120805 · Cited by 34
Pushkarsky, T., Ward, A. R., Ivanov, A. I., Lin, X., Sviridov, D., Nekhai, S. A., & Bukrinsky, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02608-2 · Cited by 33
Metadata
- Authors
- Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., & Hampel, H.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Kuopio University Hospital (FI)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 3035-3041
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145450560
- Cited by
- 586
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 38 · 2020: 40 · 2019: 44 · 2018: 34 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 34 · 2013: 33 · 2012: 43
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, p-tau231, cerebrospinal fluid biomarkers, neurofibrillary tangles, neuritic plaques, neocortex, frontal cortex, hippocampus, postmortem neuropathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Frontal Lobe, Hippocampus, Humans, Male, Parietal Lobe, Phosphorylation, Temporal Lobe, Biomarkers, Neurofibrillary Tangles, tau Proteins, Neocortex, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.